Bank of America (BofA) has adjusted its price target for Agios Pharmaceuticals (AGIO, Financial), reducing it from $54 to $52 while continuing to uphold a Buy rating on the company's stock. This change comes as part of the broader context of the Q1 earnings season, during which analysts are concentrating on the commercial launches among small to mid-cap biotech firms.
Beyond the earnings reports, discussions are expected to extend to topics such as pharmaceutical tariffs, taxation effects, and potential changes within the FDA, all of which may influence market sentiment. Despite the reduced price target, BofA remains positive about Agios Pharmaceuticals' prospects, as indicated by the maintained Buy rating.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Agios Pharmaceuticals Inc (AGIO, Financial) is $55.37 with a high estimate of $74.00 and a low estimate of $38.22. The average target implies an upside of 104.02% from the current price of $27.14. More detailed estimate data can be found on the Agios Pharmaceuticals Inc (AGIO) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Agios Pharmaceuticals Inc's (AGIO, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Agios Pharmaceuticals Inc (AGIO, Financial) in one year is $51.69, suggesting a upside of 90.46% from the current price of $27.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Agios Pharmaceuticals Inc (AGIO) Summary page.
